Ross Jennens

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial”.

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

The Lancet Oncology(2022)10.1016/s1470-2045(22)00061-4

N/A

1.5DataRank · unranked

69 citations

Silvia Novello, Alessandra Bearz, Giovanni Luca Ceresoli, Joachim G.J.V. Aerts, James Spicer +22 more

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

New England Journal of Medicine(2018)10.1056/nejmoa1801005

N/A

1.3DataRank · unranked

6524 citations

Delvys Rodríguez-Abreu, Shirish Gadgeel, Emilio Esteban, Enriqueta Felip, Flávia De Angelis +34 more